Human B cell senescence in pulmonary infections

Open Longevity Science

Volumn 6, Issue , 2012, Pages 47-55

  Blomberg, Bonnie B ^a   Frasca, Daniela ^a   Dunn Walters, Deborah ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aging; B cells; Influenza; Pneumococcus

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

B LYMPHOCYTE ACTIVATION; BACTERIAL IMMUNITY; CD8+ T LYMPHOCYTE; CELL AGING; CELL FUNCTION; CELLULAR IMMUNITY; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; ELDERLY CARE; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; LUNG INFECTION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SENESCENCE; STREPTOCOCCUS PNEUMONIA; VIRUS IMMUNITY;

EID: 84856829940     PISSN: None     EISSN: 1876326X     Source Type: Journal    
DOI: 10.2174/1876326X01206010047     Document Type: Review

References (101)

1. Centers for Disease control and Prevention [home page on the internet] Available from: http://www.cdc.gov/nchs/fastats/lcod.htm
2. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ. Bench-to-bedside review: bacterial pneumonia with influenza - pathogenesis and clinical implications. Crit Care 2010; 14: 219.
3. CDC Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus Pneumoniae. 2008 [home page on the internet] Available from: http://www.cdc.gov/abcs/reports-findings/survreports/spneu08.pdf
4. British Thoracic- Society [home page on the internet] Available from: http://www.britthoracic.org.uk/Portals/0/Library/BTS%20Publications/burdeon_of_lung_disease2007.pdf
5. Perry TW, Pugh MJ, Waterer GW, et al. Incidence of cardiovascu-lar events after hospital admission for pneumonia. Am J Med 2011; 124: 244-51.
6. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulat-ing the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983; 148: 1136-59.
7. Kruetzmann S, Rosado MM, Weber H, et al. Human immuno-globulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 939-45.
8. Kurosaki T, Aiba Y, Kometani K, Moriyama S, Takahashi Y. Unique properties of memory B cells of different isotypes. Immunol Rev 2010; 237: 104-16.
9. Tangye SG, Good KL. Human IgM+CD27+ B cells: memory B cells or memory B cells? J Immunol 2007; 179: 13-9.
10. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturi-ty of the human splenic marginal zone in infancy. Possible contri-bution to the deficient infant immune response. J Immunol 1989; 143: 3200-6.
11. Banerjee M, Sanderson JD, Spencer J, Dunn-Walters DK. Immunohistochemical analysis of ageing human B and T cell popu-lations reveals an age-related decline of CD8 T cells in spleen but not gut-associated lymphoid tissue (GALT). Mech Ageing Dev 2000; 115: 85-99.
12. Colonna-Romano G, Aquino A, Bulati M, et al. Memory B cell subpopulations in the aged. Rejuvenation Res 2006; 9: 149-52.
13. Frasca D, Landin AM, Lechner SC, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol 2008; 180: 5283-90.
14. Shi Y, Yamazaki T, Okubo Y, Uehara Y, Sugane K, Agematsu K. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J Immunol 2005; 175: 3262-7.
15. Vila-Corcoles A, Ochoa-Gondar O, Guzman JA, Rodriguez-Blanco T, Salsench E, Fuentes CM. Effectiveness of the 23-valent polysac-charide pneumococcal vaccine against invasive pneumococcal dis-ease in people 60 years or older. BMC Infect Dis 2010; 10: 73.
16. Dominguez A, Izquierdo C, Salleras L, et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010; 36: 608-14.
17. Baxendale HE, Johnson M, Keating SM, et al. Circulating pneu-mococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccina-tion. Vaccine 2010; 28: 6915-22.
18. Baxendale HE, Keating SM, Johnson M, Southern J, Miller E, Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010; 28: 4763-70.
19. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved anti-bacterial immune responses and immunological memory. Clin In-fect Dis 2008; 46: 1015-23.
20. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent poly-saccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49: 1318-25.
21. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7: 597-606.
22. Musher DM, Manof SB, Liss C, et al. Safety and antibody re-sponse, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201: 516-24.
23. Nichol KL. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010; 201: 659-61.
24. Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in mid-dle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22: 96-103.
25. Joint Committee on Vaccination and Immunisation. Statements, advice and recommendations. Department of Health. [Update: 9th July 2011] Available from: http://www.dh.gov.uk/ab/JCVI/DH_094744
26. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2(1): e00309-10.
27. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29: 281-8.
28. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persis-tence, and response to revaccination. Clin Infect Dis 1993; 17: 66-73.
29. Rubins JB, Puri AK, Loch J, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998; 178: 431-40.
30. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional anti-body activity against Streptococcus pneumoniae using differentiat-ed HL-60 cells. Clin Diagn Lab Immunol 1997; 4: 415-22.
31. Simell B, Lahdenkari M, Reunanen A, Kayhty H, Vakevainen M. Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins. Clin Vaccine Immunol 2008; 15: 1391-7.
32. Simell B, Vuorela A, Ekstrom N, et al. Aging reduces the function-ality of anti-pneumococcal antibodies and the killing of Streptococ-cus pneumoniae by neutrophil phagocytosis. Vaccine 2011; 29: 1929-34.
33. Brown JS, Hussell T, Gilliland SM, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 2002; 99: 16969-74.
34. Yuste J, Sen A, Truedsson L, et al. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from sub-jects with defects in the classical complement pathway. Infect Immun 2008; 76: 3761-70.
35. Lottenbach KR, Mink CM, Barenkamp SJ, Anderson EL, Homan SM, Powers DC. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysac-charides following vaccination. Infect Immun 1999; 67: 4935-8.
36. Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA2 response of peripheral blood lymphocytes and increases of both se-rum and secretory anti-pneumococcal antibodies. J Immunol 1988; 140: 3793-800.
37. Fukuyama Y, King JD, Kataoka K, et al. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae. J Immunol 2010; 185: 1755-62.
38. Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect Immun 2011; 79: 314-20.
39. Ademokun A, Wu YC, Martin V, et al. Vaccination-induced changes in human B cell repertoire and pneumococcal IgM and IgA antibody at different ages. Ageing Cell 2011; 10(6): 922-30.
40. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol 2000; 30: 1214-23.
41. Baxendale HE, Johnson M, Stephens RC, et al. Natural human antibodies to pneumococcus have distinctive molecular characteris-tics and protect against pneumococcal disease. Clin Exp Immunol 2008; 151: 51-60.
42. Moens L, Wuyts M, Meyts I, De Boeck K, Bossuyt X. Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol 2008; 181: 5306-12.
43. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbil-ical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70. J Exp Med 2011; 208: 67-80.
44. Zhou J, Lottenbach KR, Barenkamp SJ, Lucas AH, Reason DC. Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Strep-tococcus pneumoniae type 23F. Infect Immun 2002; 70: 4083-91.
45. Zhou J, Lottenbach KR, Barenkamp SJ, Reason DC. Somatic hypermutation and diverse immunoglobulin gene usage in the hu-man antibody response to the capsular polysaccharide of Strepto-coccus pneumoniae Type 6B. Infect Immun 2004; 72: 3505-14.
46. Wu YC, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 2010; 116: 1070-8.
47. Zangeneh TT, Baracco G, Al-Tawfiq JA. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumo-coccal infections. Expert Rev Vaccines 2011; 10: 345-53.
48. Loerbroks ASC, Bosch JA, Litaker DG, Apfelbacher CJ. Influenza vaccination coverage among high-risk groups in 11 European coun-tries. Eur J Public Health 2011. [Epub ahead of print].
49. Zimmerman RK, Lauderdale DS, Tan SM, Wagener DK. Preva-lence of high-risk indications for influenza vaccine varies by age, race, and income. Vaccine 2010; 28: 6470-7.
50. Ferrucci L, Guralnik JM, Pahor M, Corti MC, Havlik RJ. Hospital diagnoses, Medicare charges, and nursing home admissions in the year when older persons become severely disabled. JAMA 1997; 277: 728-34.
51. Monto AS, Ansaldi F, Aspinall R, et al. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009; 27: 5043-53.
52. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Com-mittee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2011; 59: 1-62.
53. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37: 529-49.
54. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of im-mune protection induced by live, attenuated, cold-adapted, triva-lent, intranasal influenza virus vaccine. J Infect Dis 2000; 181: 1133-7.
55. Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol 2002; 37: 427-39.
56. Epstein SL, Misplon JA, Lawson CM, Subbarao EK, Connors M, Murphy BR. Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuramini-dase. J Immunol 1993; 150: 5484-93.
57. Saelens X, Vanlandschoot P, Martinet W, et al. Protection of mice against a bent assay after primary or secondary infection of humans with influenza A virus. Infect Immun 1983; 41: 540-5.
58. McMurry JA, Johansson BE, De Groot AS. A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin 2008; 4: 148-57.
59. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453: 667-71.
60. Corti D, Suguitan AL Jr., Pinna D, et al. Heterosubtypic neutraliz-ing antibodies are produced by individuals immunized with a sea-sonal influenza vaccine. J Clin Invest 2010; 120: 1663-73.
61. Goodwin K, Viboud C, Simonsen L. Antibody response to influen-za vaccination in the elderly: a quantitative review. Vaccine 2006; 24: 1159-69.
62. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2011; 10(3): 379-88.
63. McElhaney JE, Effros RB. Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol 2009; 21: 418-24.
64. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mor-tality benefits of influenza vaccination in elderly people: an ongo-ing controversy. Lancet Infect Dis 2007; 7: 658-66.
65. Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine 2007; 25: 3066-9.
66. Ahmed AE, Nicholson KG, Nguyen-Van-Tam JS. Reduction in mortality associated with influenza vaccine during 1989-90 epi-demic. Lancet 1995; 346: 591-5.
67. Keitel WA, Cate TR, Couch RB. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine. Am J Epidemiol 1988; 127: 353-64.
68. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333-40.
69. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27.
70. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998; 178: 53-60.
71. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effective-ness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002; 20: 1831-6.
72. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influ-enza vaccine field effectiveness. Vaccine 2006; 24: 6605-11.
73. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84.
74. DelaRosa O, Pawelec G, Peralbo E, et al. Immunological bi-omarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology 2006; 7: 471-81.
75. Effros RB. Genetic alterations in the ageing immune system: im-pact on infection and cancer. Mech Ageing Dev 2003; 124: 71-7.
76. Franceschi C, Valensin S, Bonafe M, et al. The network and the remodeling theories of aging: historical background and new per-spectives. Exp Gerontol 2000; 35: 879-96.
77. Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM. Aging of the innate immune system. Curr Opin Immunol 2010; 22: 507-13.
78. Solana R, Pawelec G, Tarazona R. Aging and innate immunity. Immunity 2006; 24: 491-4.
79. Jing Y, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. Hum Immunol 2009; 70: 777-84.
80. Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol 2010; 184: 2518-27.
81. Sridharan A, Esposo M, Kaushal K, et al. Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity. Age (Dordr) 2011; 33(3): 363-76.
82. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting re-sponsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182-7.
83. Goronzy JJ, Lee WW, Weyand CM. Aging and T-cell diversity. Exp Gerontol 2007; 42: 400-6.
84. Gupta S, Bi R, Su K, Yel L, Chiplunkar S, Gollapudi S. Characteri-zation of naive, memory and effector CD8+ T cells: effect of age. Exp Gerontol 2004; 39: 545-50.
85. Pawelec G, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence: is it infectious? Immunol Rev 2005; 205: 257-68.
86. Pawelec G, Barnett Y, Forsey R, et al. T cells and aging, January 2002 update. Front Biosci 2002; 7: d1056-183.
87. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005; 205: 158-69.
88. Olsson J, Wikby A, Johansson B, Lofgren S, Nilsson BO, Ferguson FG. Age-related change in peripheral blood T-lymphocyte subpop-ulations and cytomegalovirus infection in the very old: the Swedish longitudinal OCTO immune study. Mech Ageing Dev 2000; 121: 187-201.
89. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. Rev Med Virol 2009; 19: 47-56.
90. Chong Y, Ikematsu H, Yamaji K, et al. CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell devel-opmental disturbances. Int Immunol 2005; 17: 383-90.
91. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011; 10(3): 330-5.
92. Frasca D, Blomberg BB. Effects of aging on B cell function. Curr Opin in Immunol 2009; 21: 425-30.
93. Linton PJ, Dorshkind K. Age-related changes in lymphocyte devel-opment and function. Nat Immunol 2004; 5: 133-9.
94. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168: 5893-9.
95. Shahid Z, Kleppinger A, Gentleman B, Falsey AR, McElhaney JE. Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine 2010; 28: 6145-51.
96. Frasca D, Diaz A, Romero M, et al. Intrinsic defects in B cell re-sponse to seasonal influenza vaccination in elderly humans. Vac-cine 2010; 28(51): 8077-84.
97. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-15.
98. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of sero-logical memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-202.
99. Manz RA, Radbruch A. Plasma cells for a lifetime? Eur J Immunol 2002; 32: 923-7.
100. Sasaki S, Jaimes MC, Holmes TH, et al. Comparison of the influ-enza virus-specific effector and memory B-cell responses to im-munization of children and adults with live attenuated or inactivat-ed influenza virus vaccines. J Virol 2007; 81: 215-28.
101. Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inacti-vated influenza vaccine in elderly individuals is associated with de-creased production of vaccine-specific antibodies. J Clin Invest 2011;121(8): 3109-19.